Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025

Ocular Therapeutix Inc -2.67%

Ocular Therapeutix Inc

OCUL

7.28

-2.67%

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company's strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via